FATE
FATE
NASDAQ · Biotechnology

Fate Therapeutics Inc

$1.28
-0.06 (-4.48%)
As of Nov 14, 10:38 PM ET ·
Financial Highlights (FY 2026)
Revenue
6.15M
Net Income
-126,304,185
Gross Margin
—
Profit Margin
-2,051.1%
Rev Growth
-59.0%
D/E Ratio
0.05
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 63.6% 63.6%
Operating Margin -2,222.4% -2,000.2% -24.4% -27.5%
Profit Margin -2,051.1% -1,948.5% -25.6% -22.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 6.15M 15.00M 39.14M 43.52M
Gross Profit — — 24.91M 27.70M
Operating Income -136,744,170 -300,023,776 -9,536,619 -11,955,209
Net Income -126,304,185 -277,117,909 -10,010,485 -9,808,127
Gross Margin — — 63.6% 63.6%
Operating Margin -2,222.4% -2,000.2% -24.4% -27.5%
Profit Margin -2,051.1% -1,948.5% -25.6% -22.5%
Rev Growth -59.0% -59.0% +22.5% +8.4%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 3.95M 3.95M 13.35M 16.76M
Total Equity 77.50M 77.50M 48.97M 54.56M
D/E Ratio 0.05 0.05 0.27 0.31
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -124,906,308 -289,275,944 -16,322,152 -16,265,725
Free Cash Flow — — -10,981,777 -9,671,173